Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Total Liabilities (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of Total Liabilities data on record, last reported at $3.3 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 17.84% year-over-year to $3.3 million; the TTM value through Sep 2025 reached $3.3 million, down 17.84%, while the annual FY2024 figure was $5.0 million, 34.18% up from the prior year.
  • Total Liabilities reached $3.3 million in Q3 2025 per COEP's latest filing, down from $5.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $10.4 million in Q2 2021 and bottomed at $2.8 million in Q3 2023.
  • Average Total Liabilities over 5 years is $5.0 million, with a median of $4.6 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: tumbled 60.64% in 2022, then skyrocketed 43.04% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $4.4 million in 2021, then decreased by 21.58% to $3.5 million in 2022, then rose by 8.51% to $3.8 million in 2023, then skyrocketed by 34.18% to $5.0 million in 2024, then crashed by 35.24% to $3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $3.3 million in Q3 2025, $5.1 million in Q2 2025, and $6.0 million in Q1 2025.